

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/CDB38C9B37FEN.html>

Date: September 2018

Pages: 110

Price: US\$ 3,500.00 (Single User License)

ID: CDB38C9B37FEN

Abstracts

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

SUMMARY

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 22 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2018, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 3, 4 and 4 respectively. Similarly, the universities portfolio in

Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology, Respiratory and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Ovarian Cancer, Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM), Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Hematological Tumor, Hepatic - Colorectal Metastasis, Kidney Transplant Rejection, Leukemias, Malignant Pleural Effusion, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Prostate Cancer, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Solid Tumor.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects

The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development

Actavalon Inc

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles

APR-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-14022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBS-9106 - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
contusugene ladenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYN-00103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MHY-449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MJ-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Viruses to Activate p53 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSE-2101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPAL-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QPI-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SGT-53 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate p53 for Oncology and Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZMC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones

Featured News & Press Releases

Jul 09, 2018: Quark Pharmaceuticals Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery

Jul 05, 2018: OSE Immunotherapeutics Receives a €435,000 Translational Research Grant to Develop Precision Medicine Targeting for Tedopi

Jul 02, 2018: OSE Immunotherapeutics Receives IDMC Approval to Continue "Atalante 1" Phase 3 NSCLC Clinical Trial of Tedopi

Jun 17, 2018: Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm

Jun 05, 2018: Stemline Therapeutics Announces Positive Data Presentations on SL-801 at ASCO

May 24, 2018: Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program

May 17, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting

May 17, 2018: Stemline Therapeutics Announces Presentation of SL-801 Clinical Data at the Upcoming ASCO Annual Meeting

Apr 26, 2018: Stemline Therapeutics Announces Clinical Presentation of SL-801 at the Upcoming ASCO Annual Meeting

Apr 16, 2018: Karolinska Development's portfolio company Aprea presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine for the treatment of Mutant Myelodysplastic Syndromes

Apr 03, 2018: Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Mar 26, 2018: Combination breast cancer therapy targets both tumor cells and the blood vessels that supply them, MU researchers find

Mar 20, 2018: Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

Mar 15, 2018: OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

Feb 27, 2018: OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Products under Development by Companies, H2 2018 (Contd.2), H2 2018
Products under Development by Companies, H2 2018 (Contd.3), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Actavalon Inc, H2 2018
Pipeline by Aprea AB, H2 2018
Pipeline by CanBas Co Ltd, H2 2018
Pipeline by Cotinga Pharmaceuticals Inc, H2 2018
Pipeline by Innovation Pharmaceuticals Inc, H2 2018
Pipeline by ORCA Therapeutics BV, H2 2018
Pipeline by OSE Immunotherapeutics, H2 2018
Pipeline by Quark Pharmaceuticals Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Dormant Products, H2 2018 (Contd.2), H2 2018
Dormant Products, H2 2018 (Contd.3), H2 2018
Dormant Products, H2 2018 (Contd.4), H2 2018
Dormant Products, H2 2018 (Contd.5), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Actavalon Inc

Aprea AB

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Quark Pharmaceuticals Inc

I would like to order

Product name: Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/CDB38C9B37FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CDB38C9B37FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

